Saniona AB (publ) (SANION) Earnings Call Transcripts

Saniona AB (publ)'s Latest Earnings Call - June 17, 2026

In the Q2 2026 earnings call for Saniona AB, the focus was primarily on the promising preclinical data for SAN2668, a treatment for developmental and epileptic encephalopathies (DEE). Management highlighted the drug's potential to provide robust seizure control while minimizing side effects associated with current benzodiazepines. Revenue and earnings figures were not disclosed, but the company signaled a commitment to advancing SAN2668 into human trials by year-end, indicating a strategic shift towards addressing significant unmet medical needs in pediatric epilepsy. This could position Saniona favorably in a high-value market segment.

Reported metrics

Guidance from management

Management indicated plans to advance SAN2668 into human trials by year-end 2026, with a focus on utilizing biomarkers for early efficacy readouts.

What management said

Yes, Thomas. Just pull on some questions that have come in through the audience here. First question that's come in. Can you talk about why SAN2668 is ultimately the right focus for Saniona's next chapter?

The next question is again -- is can you talk about what does 2668 selectivity profile enable that earlier alpha 2 or alpha 3 selective positive allosteric modulators couldn't achieve?

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape for DEE treatments and the potential need for additional funding to support the larger Phase II study. There were questions about the timeline for clinical data and the drug's differentiation from existing therapies.

Main topics on the call

• SAN2668 Preclinical Data — Management presented compelling preclinical evidence showing that SAN2668 effectively suppresses seizures and spike wave discharges, which are critical in DEEs. Dr. Karin Nielsen stated, "2668 shows quite strong preclini...
• Clinical Development Strategy — Saniona outlined a detailed clinical development strategy for SAN2668, emphasizing the use of validated biomarkers for rapid derisking. Dr. Pierandrea Muglia noted, "We have defined a developmental strategy that can gene...
• Market Opportunity — The management underscored the significant commercial potential of SAN2668 in the pediatric epilepsy market, which is characterized by high unmet needs. Thomas Feldthus remarked, "This drug seems addressing net for dysfu...
• Efficacy Beyond Seizure Control — Management emphasized that SAN2668 may also address behavioral and cognitive impairments associated with DEEs, which are often overlooked in current treatments. Dr. Nicola Specchio stated, "If we're able to complete the ...

Read the full Saniona AB (publ) transcript (June 17, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 Saniona AB (publ) earnings call transcripts on record, spanning November 24, 2020 to June 17, 2026. Based on this history, Saniona AB (publ) reports annually. The most recent call on file is dated June 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SANION

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

9

First call

November 24, 2020

Most recent

June 17, 2026

Reporting cadence

annually